Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

To compare quality of life (QoL) and treatment satisfaction in patients with Type 1 diabetes receiving the rapid-acting insulin analogue, insulin aspart (IAsp), with that in patients receiving soluble human insulin (HI).

Who Took Part

The abstract describes 424 patients taking part.

PubMed indexes the participants as adults, both men and women.

In this 6-month, multinational, randomized, open-label trial, 424 patients from German-speaking countries were subjected to psychometric assessment before and after randomization (ratio 2 : 1) to basal-bolus treatment with either IAsp (n = 283) or HI (n = 141).

Patients on HI were advised to keep an injection-meal interval of 30 min, whereas patients on IAsp were advised to inject immediately before meals.

How the Study Was Run

In design terms this was a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Being open-label, the Insulin Aspart study did not mask who received what.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Aspart, Patient Satisfaction, Quality of Life and Regression Analysis.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart in 424 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Aspart compound page, all human trials.